Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens

Journal of Clinical Pharmacology

Volumn 55, Issue 9, 2015, Pages 985-994

  Spyker, Daniel A ^a   Riesenberg, Robert A ^b   Cassella, James V ^a  

^a Alexza Pharmaceuticals   (United States)

^b Atlanta Center for Medical Research   (United States)

Author keywords

ADASUVE; agitation; inhaled loxapine; multiple dose; pharmacodynamics; pharmacokinetics; Staccato

Indexed keywords

LOXAPINE; NEUROLEPTIC AGENT; PLACEBO; QUETIAPINE;

ADULT; AEROSOL; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY DEVICE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; HUMAN; HYPESTHESIA; HYPOTENSION; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RATE CONSTANT; SEDATION; SOMNOLENCE; STATISTICAL ANALYSIS; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN; BLOOD; HALF LIFE TIME; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED;

ADMINISTRATION, INHALATION; ADULT; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; LOXAPINE; MALE; MIDDLE AGED;

EID: 84937734736     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.502     Document Type: Article

References (34)

1. Osser DN, Sigadel R. Short-term inpatient pharmacotherapy of schizophrenia. Harv Rev Psychiatry. 2001;9: 89-104.
2. Alderfer BS, Allen MH. Treatment of agitation in bipolar disorder across the life cycle. J Clin Psychiatry. 2003; 64(suppl): 3-9.
3. Conn DK, Lieff S. Diagnosing and managing delirium in the elderly. Can Fam Physician. 2001; 47: 101-108.
4. Battaglia J. Pharmacological management of acute agitation. Drugs. 2005; 65: 1207-1222.
5. Buckley PF. The role of typical and atypical antipsychotic medications in the management of agitation and aggression. J Clin Psychiatry. 1999; 60(suppl 10): 52-60.
6. Heel RC, Brogden RN, Speight TM, Avery GS. Loxapine: a review of its pharmacological properties and therapeutic efficacy as an antipsychotic agent. Drugs. 1978; 15 (3): 198-217.
7. Chakrabarti A, Bagnall AM, Chue P, Fenton M, Palaniswamy V, Wong W, Xia J. Loxapine for schizophrenia. Cochrane Database Syst Rev. 2007: Art. No.: CD001943. doi: 10.1002/14651858.CD001943.pub2.
8. Paprocki J, Versiani M. A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia. Curr Ther Res Clin Exp. 1977;21: 80-100
9. Fruensgaard K, Korsgaard S, Jorgensen H, Jensen K. Loxapine versus haloperidol parenterally in acute psychosis with agitation. A double-blind study. Acta Psychiatr Scand. 1977; 56: 256-264.
10. Dubin WR, Weiss KJ. Rapid tranquilization: a comparison of thiothixene with loxapine. J Clin Psychiatry. 1986; 47: 294-297.
11. Gaussares C, Gerard H, Bosc M. Interest in injectable Loxapine for severe agitation. Inf Psychiatr. 1989; 69: 656-660.
12. Glazer WM. Does loxapine have "atypical" properties? Clinical evidence. J Clin Psychiatry. 1999; 60(suppl 10): 42-46.
13. Bourdinard V, Pochard F. Survey of management methods for patients in a state of agitation at admissions and emergency departments in France. Encephale. 2003; 29: 89-98.
14. Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002; 59: 441-448.
15. Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: arandomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007; 68: 111-119.
16. Wright P, Birkett M, David SR, Meehan K, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry. 2001; 158: 1149-1151.
17. Battaglia J, Lindborg SR, Alaka K, Meehan K, Wright P. Calming versus sedative effects of intramuscular olanzapine in agitated patients. Am J Emerg Med. 2003; 21: 192-198.
18. Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: a multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011; 198 (1): 51-58.
19. Kwentus J, Riesenberg RA, Marandi M, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicentre, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012; 14: 31-40.
20. Spyker DA, Munzar P, Cassella JV. Pharmacokinetics of loxapine following inhalation of a thermally-generated aerosol in healthy volunteers. J Clin Pharmacol. 2010; 50: 169-179.
21. Rabinowitz JD, Wensley M, Lloyd P, et al. Fast onset medications through thermally generated aerosols. J Pharmacol Exp Ther. 2004; 309: 769-775.
22. Rabinowitz JD, Lloyd PM, Munzar P, et al. Ultra-fast absorption of amorphous pure drug aerosols via deep lung inhalation. J Pharm Sci. 2006; 95: 2438-2451.
23. Heyder J. Particle transport onto human airway surfaces. Eur J Respir Dis Suppl. 1982; 119: 29-50.
24. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry. 2001; 62: 153-157.
25. Currier GW, Chou JC, Feifel D, Bossie CA, Turkoz I, Mahmoud RA, Gharabawi GM. Acute treatment of psychotic agitation: a randomized comparison of oral treatment with risperidone and lorazepam versus intramuscular treatment with haloperidol and lorazepam. J Clin Psychiatry. 2004; 65: 386-394.
26. Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J. 2003; 20: 339-346.
27. Cooper TB, Kelly RG. GLC analysis of loxapine, amoxapine, and their metabolites in serum and urine. J Pharm Sci. 1979; 68: 216-219.
28. Midha KK, Hubbard JW, McKay G, Hawes EM, Hsia D. The role of metabolites in a bioequivalence study 1: loxapine, 7-hydroxyloxapine and 8-hydroxyloxapine. Int J Clin Pharmacol Ther Toxicol. 1993; 31: 177-183.
29. Simpson GM, Cooper TB, Lee JH, Young MA. Clinical and plasma level characteristics of intramuscular and oral loxapine. Psychopharmacology (Berl). 1978; 56: 225-232.
30. Zhang JY, Wang Y, Prakash C. Xenobiotic-metabolizing enzymes in human lung. Curr Drug Metab. 2006; 7: 939-948.
31. Burch EA Jr, Goldschmidt TJ. Loxapine in the treatment of psychotic-depressive disorders: Measurement of antidepressant metabolites. South Med J. 1983; 76: 991-995.
32. Cheung SW, Tang SW, Remington G. Simultaneous quantitation of loxapine, amoxapine and their 7- and 8-hydroxy metabolites in plasma by high-performance liquid chromatography. J Chromatogr. 1991; 564: 213-221.
33. Coupet J, Rauh CE. 3H-Spiroperidol binding to dopamine receptors in rat striatal membranes: influence of loxapine and its hydroxylated metabolites. Eur J Pharmacol. 1979; 55: 215-218.
34. Spyker DA, Voloshko P, Heyman ER, Cassella JV. Loxapine delivered as a thermally generated aerosol does not prolong QTc in a thorough QT/QTc study in healthy subjects. J Clin Pharmacol. 2014; 54 (6): 665-674.